Dublin, April 06, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.
This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.
Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.
Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.
The cell-based markets was analyzed for 2016, and projected to 2026.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 305 of these are profiled in part II of the report along with tabulation of 291 alliances. Of these companies, 170 are involved in stem cells.
Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 64 Tables and 22 Figures. The bibliography contains 1,200 selected references, which are cited in the text.
Key Topics Covered:
Part I: Technologies, Ethics & Regulations
Executive Summary
1. Introduction to Cell Therapy
2. Cell Therapy Technologies
3. Stem Cells
4. Clinical Applications of Cell Therapy
5. Cell Therapy for Cardiovascular Disorders
6. Cell Therapy for Cancer
7. Cell Therapy for Neurological Disorders
8. Ethical, Legal and Political Aspects of Cell therapy
9. Safety and Regulatory Aspects of Cell Therapy
Part II: Markets, Companies & Academic Institutions
10. Markets and Future Prospects for Cell Therapy
11. Companies Involved in Cell Therapy
12. Academic Institutions
13. References
For more information about this report visit http://www.researchandmarkets.com/research/s5g673/cell_therapy
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics


Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 



